



# INNOVATIONS IN COVID-19

Bridging opportunities  
at Oswaldo Cruz Institute

## EVALUATION OF THE SUSCEPTIBILITY OF ANIMAL MODELS TO SARS-COV-2 INFECTION AIMING AT PROVING THE EFFICACY AND SAFETY OF NEW SUBSTANCES OF PROMISING ANTIVIRAL ACTIVITY (COD. 2020.023-A)

### COORDINATOR

Marcelo Alves Pinto

### RESEARCH AREA

New Drugs

### DEVELOPMENT STAGE

Level 4 - TRL - Component and/or breadboard validation in laboratory environment.  
MRL - Capability to produce the technology in a laboratory environment

### PROPOSITION / APPLICATION

New evidence of drugs with promising potential and derived exclusively from observational data or from clinical tests performed with small samples, may pose a greater risk of bias or imprecision.

### INNOVATION

Evaluation of pulmonary and antiviral anti-inflammatory activities of a compound for the treatment of COVID-19

### OPPORTUNITY

Development of new drugs of pulmonary and antiviral anti-inflammatory activity for COVID-19

### CONTACT

[nit@ioc.fiocruz.br](mailto:nit@ioc.fiocruz.br)